Federal Register Notice: FDA is seeking public comment on the proposed collection of information on interviews of pharmaceutical manufacturers who submit new molecular entity NDAs and original BLAs to FDA under the Program for Enhanced Review Transparency and Communication during fiscal years 2013-2017. Comments should be submitted by 4/22. To view this notice, click here.
